Drug news
FDA approves Absorica (Ranbaxy) for severe Acne
FDA has approved Absorica on 25 May 2012, a patented formulation of isotretinoin, as a treatment for severe recalcitrant nodular acne. Ranbaxy is expected to launch Absorica in the USA in the fourth-quarter 2012.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.